EXINI Executes Agreement with Bayer AG for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
As of November 2022, EXINI has entered into an agreement with Bayer AG to integrate its artificial intelligence (AI) enabled software as a medical devices – aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation) and aBSI® (Automated Bone Scan Index), into Bayer medical imaging platform CalanticTM Digital Solutions.
EXINIs’ proprietary platform aPROMISE, developed to standardized quantification of prostate-specific membrane antigen (PSMA) PET/CT imaging used in the evaluation of prostate cancer, is already in use at prominent academic medical centers in the U.S. Through these new collaborations, the AI technology can be broadly distributed and integrated into the leading workstation systems that facilitate nuclear medicine clinical workflow across the majority of PET sites in the U.S. and Europe.
Read more about aPROMISE
The automated Bone Scan Index (aBSI) technology, developed by EXINI Diagnostics AB, gives a fully quantitative assessment of bone scans that incorporates inferred masses of all lesions.
Read more about aBSI